HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial


TRATAMENTO NEOADJUVANTE COM TDM1+ PERTUZUMAB FOI MUITO BEM ACEITO POR 95% DOS PACIENTES COM PCR : 55% , LEVANDO EM CONTA HETEROGENIDADE TUMORAL DO HER -2 , ESTAR INDEPENDENTE DO RECEPTOR DE ESTROGÊNIO , A HETEROGENIEDADE INTRATUMORAL PODE ESTAR ASSOCIADO A BAIXA TAXA DE RESPOSTA PATOLÓGICA , BAIXO NÍVEL DE EXPRESSÃO PROTEÍNA HER2 


















Comentários

Postar um comentário

Postagens mais visitadas deste blog

Imagem
 https://sabcs.onlineeventpro.freeman.com/posters/25581279/Efficacy-and-tolerability-of-neoadjuvant-Pertuzumab-Trastuzumab-and-weekly-Paclitaxel-in-Locally-advanced-Her-2-positive-Breast-cancer https://sabcs.onlineeventpro.freeman.com/posters/25582333/Phase-II-pilot-study-of-trastuzumab-biosimilar-herzuma-plus-gedatolisib-in-patients-with-HER-2-positive-metastatic-breast-cancer-who-progressed-after-2-or-more-HER-2-directed https://sabcs.onlineeventpro.freeman.com/posters/25581672/HER2CLIMB-02-A-randomized-double-blind-phase-3-study-of-tucatinib-or-placebo-with-T-DM1-for-unresectable-locally-advanced-or-metastatic-HER2-breast-cancer          
Leia mais